publication date: Oct. 20, 2017

In Brief Dana-Farber joins the Parker Institute for Cancer Immunotherapy

The Parker Institute for Cancer Immunotherapy said researchers at Dana-Farber Cancer Institute have joined its network.

Leadership at both institutions has identified projects that support the Parker Institute’s strategic roadmap. Projects include those focused on basic mechanisms underlying checkpoint inhibitor resistance and immune activation and priming. Clinical research could include trials that integrate checkpoint therapies with cancer vaccines. In many cases, these projects will be collaborations with Parker Institute investigators at other institutions.

The Parker Institute created a flexible model to easily expand its network and recruit world-class talent like the researchers at Dana-Farber. The researchers joining the Parker Institute include:

Nick Haining is a physician-scientist at Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT who studies the mechanisms underlying T cell exhaustion and immune evasion by tumors. Haining’s lab uses cellular immunology, functional genomics, epigenetics, and single cell profiling to understand why protective T cell memory fails to occur in cancer and chronic viral infection, and how tumors avoid immune attack.

Catherine Wu is a physician-scientist with expertise in cancer genomics, immunogenomics, and the design and testing of personalized cancer vaccines. A major priority of her studies is the identification of tumor-specific antigens that would allow effective tumor targeting without collateral toxicity. She is an … Continue reading Dana-Farber joins the Parker Institute for Cancer Immunotherapy

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.